BCL2 and breast carcinoma: The expression of BCL2 has been included in molecular panels determining the risk of recurrence and adjuvant treatment setting, such as Oncotype DX and PAM50-based–Prosigna Breast Cancer Prognostic Gene Signature Assay [18].